Cholesterol ManagementMay 19, 2026
Across multiple human studies, including randomized trials, long-term treatment data, and post-surgical follow-ups, atorvastatin does not appear to cause weight gain. That is not a hedged, "maybe-maybe-not" conclusion. It is a consistent finding that shows up in different patient populations, at different doses, and over different timeframes. If the number on your scale is climbing while you take atorvastatin, the research strongly suggests something else is responsible.
This matters because statins are among the most widely prescribed drugs in the world, and weight concerns are one of the reasons people consider stopping them. The evidence available gives a clear picture worth understanding.
GLP-1May 19, 2026
In SURMOUNT-1, the largest trial of Zepbound for weight management, people without diabetes lost an average of 20.9% of their body weight on the 15 mg dose over 72 weeks. For someone starting at 240 pounds, that's roughly 50 pounds.
That's the average. The reality across thousands of trial participants is more textured: weight loss starts within weeks, accelerates through month 6, slows by month 12, and depends heavily on which dose you tolerate.
Body composition shifts in ways the scale doesn't show. Blood pressure, triglycerides, waist size, and HbA1c move alongside the weight. And when people stop taking the drug, much of what they lost comes back.
GLP-1May 19, 2026
In the trial that got Zepbound approved, the average person on the highest 15 mg dose lost 20.9% of their body weight over 72 weeks. The 10 mg dose was 19.5%, and the 5 mg dose was 15.0%. The highest dose wins on paper, but only by 1.4 percentage points over 10 mg, while gastrointestinal side effects keep rising and discontinuation creeps up.
If you're thinking about Zepbound, the more useful question isn't which dose produces the absolute most weight loss in a trial. It's which dose produces the most weight loss YOU can actually stay on for a year or longer. Those answers can differ.
ProbioticsMay 19, 2026
A single randomized controlled trial gave pasteurized Akkermansia muciniphila to overweight, insulin-resistant adults for three months. The results were genuinely impressive: insulin sensitivity improved roughly 29%, fasting insulin dropped, total cholesterol fell, and participants lost modest amounts of weight and fat mass. Short-term safety looked good. That's the best news this bacterium has going for it right now, and it's worth taking seriously.
It's also worth taking carefully. That one trial is, so far, the only controlled human experiment with direct Akkermansia supplementation. The rest of the evidence comes from animal research and observational data, and some of it raises real concerns about who might be helped and who might be harmed.
GLP-1May 19, 2026
Zepbound's pen authorizes three injection sites (abdomen, thigh, and upper arm), and pharmacokinetic data show the drug absorbs about the same regardless of which one you use. The catch is what happens to the skin underneath after weeks of injecting in roughly the same place: a fibrofatty thickening called lipohypertrophy, which affects up to 60% of long-term self-injecting diabetes patients.
If you're holding your first Zepbound pen and wondering which site to use, the answer is: any of the three. The bigger question is what you'll do over the months that follow. Where you keep returning the needle, more than where you start, decides whether the medication still absorbs as expected after dozens of doses.
GLP-1May 19, 2026
In the landmark trial that got Zepbound approved, the average person on the 15 mg dose lost 20.9% of their starting body weight over 72 weeks. That number gets quoted constantly in marketing copy, but it hides three things every prospective patient should know: results depend heavily on dose, real-world losses tend to be smaller, and the weight comes back fast if you stop the drug.
This is what tens of thousands of patients across clinical trials and real-world studies tell us about what to actually expect.
GLP-1May 19, 2026
After 176 weeks on tirzepatide, the largest obesity trial reported "no new safety signals." That's the headline from the 3-year SURMOUNT-1 follow-up of 2,539 adults with obesity, in which the 15 mg dose produced a 19.7% weight loss with the same gastrointestinal-dominated side-effect pattern visible in year one.
That's reassuring, but it doesn't answer the harder questions. Are the cardiovascular signals from the SURPASS program holding up, what does the lean-mass loss mean over years, and what happens when you stop?
Long-term safety for tirzepatide rests on three pillars: the SURPASS trials in type 2 diabetes (up to 104 weeks), the SURMOUNT trials in obesity (up to 176 weeks), and pharmacovigilance databases tracking real-world reports. Together they paint a consistent picture, with a few areas worth watching.
DiabetesMay 19, 2026
Jardiance (empagliflozin) reliably shaves off about 2 to 3 kilograms in people with type 2 diabetes, roughly 3 to 4% of body weight over three to six months. That's consistent and measurable, but it puts Jardiance firmly in the "mild" weight loss category, well below the 10%-plus losses seen with GLP-1 medications like semaglutide. If you're taking Jardiance and noticing the scale drift downward, that's expected. If you're considering it primarily for weight loss, the research suggests you'd be disappointed.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class of drug designed to manage type 2 diabetes, heart failure, and kidney disease. Weight loss is a real but secondary effect, more of a metabolic bonus than the main event.
CortisolMay 19, 2026
The supplements that lower cortisol in clinical trials are largely different from the ones that reduce visceral (belly) fat. That distinction matters, because the two goals require separate strategies. Ashwagandha has the most consistent evidence for lowering cortisol, while specific probiotic strains and certain plant polyphenols show the most promise for visceral fat reduction.
But "promise" deserves a reality check. Effects across the board are moderate, require at least 8 to 16 weeks, and none of these supplements replace calorie control, exercise, and sleep for fat loss and health.
Digestive DisordersMay 19, 2026
Psyllium, the single ingredient in Metamucil, has clinical trial evidence behind four distinct health outcomes: relieving constipation, lowering LDL cholesterol, improving blood sugar control in type 2 diabetes, and supporting modest weight loss. That makes it one of the best-studied fiber supplements you can buy.
The catch is that these results consistently require around 10 grams per day or more, taken for at least several weeks. A single spoonful on a random Tuesday morning probably isn't doing much.
GLP-1May 19, 2026
Retatrutide is a triple-receptor agonist (GLP-1, GIP, and glucagon) being developed by Eli Lilly for obesity and type 2 diabetes. It is not yet FDA-approved, but phase 2 trial data give a detailed picture of its side effect profile. If you are exploring GLP-1 medications that are available today, Zepbound (tirzepatide) is the closest approved option.
SupplementationMay 19, 2026
Isolated soluble fibers, the same types used in most fiber gummies (inulin, fructooligosaccharides, resistant starch), produce small but measurable improvements in body weight, blood sugar, and body composition. In adults with overweight or obesity, these fiber supplements reduced body weight by roughly 2.5 kg, along with improvements in BMI, body fat, fasting glucose, and insulin, over study periods ranging from 2 to 17 weeks.
That's a genuine effect, not a marketing fantasy. But it's also not the whole story. Most of the big, impressive health associations tied to fiber come from diets rich in whole plant foods, which bundle fiber with micronutrients and phytochemicals that an isolated supplement simply doesn't contain. Fiber gummies occupy a real but narrow lane.
Weight ManagementMay 18, 2026
A 1.6-gram dose of beta-alanine triggers pins-and-needles tingling on the arms, neck, and trunk in most people who take it as a powder or solution. Put the same 1.6 grams in a sustained-release tablet and the tingling drops to roughly placebo levels. Same molecule, same dose, very different experience.
The form you take matters more than the amount.
If you take pre-workout, you probably know the feeling: that crawling tingle that hits your scalp, ears, or upper chest a few minutes after the scoop goes down. It is not an allergy and it is not a warning sign. It is one of the cleanest examples in neuroscience of a single molecule activating a single receptor on a specific kind of skin nerve.
Once you know what is going on, the workaround is obvious.
Weight ManagementMay 18, 2026
If you are starting Repatha and you have heard horror stories about cholesterol medications and weight gain, the trial evidence is reassuring. Across 27,564 patients followed for a median of 2.2 years, Repatha (evolocumab) produced no excess in new-onset diabetes, no shift in glycemic markers, and no overall adverse-event difference compared to placebo. Weight gain is not among the adverse events the trial flagged; the only excess was mild injection-site reactions at 2.1% vs 1.6%.
This matters because the question of "does this cholesterol drug make me gain weight" gets asked about almost every lipid-lowering medication, even though the underlying mechanisms differ completely. Repatha sits in a different drug class than the medications that built that reputation, and its safety profile in trials reflects that difference.
NutritionMay 18, 2026
Protein bars can be a healthy, convenient protein source, but many commercial options are loaded with added sugars, unhealthy fats, and additives that undermine their supposed health benefits. A study of foods with protein claims in Spain found that products carrying protein labels were actually 13% more likely to be classified as "less healthy" by objective nutrient profiling standards than products without such claims.
The word "protein" on the package doesn't guarantee you're making a good choice. This article will walk you through exactly what to look for when you flip that bar over, with specific numbers and red flags backed by clinical research.
Weight ManagementMay 18, 2026
Spironolactone does not cause clinically meaningful weight gain. Across every population studied, from heart failure patients to women with PCOS to obese postmenopausal women, the pattern is consistent: weight either stays the same or drops slightly. In one large cardiovascular trial with over 1,700 patients, spironolactone actually cut the odds of gaining significant weight nearly in half during the first year.
That's a notably clean signal for a medication many people worry about. If you've been prescribed spironolactone and Googled the side effects list, you may have seen "weight gain" mentioned. The clinical evidence tells a different story.
InsulinMay 17, 2026
Insulin's side effect profile is narrower than many people assume. Large, long-term trials point to just three main concerns: low blood sugar, modest weight gain, and local skin reactions at injection sites. Fears about insulin causing cancer or heart disease? Not supported by high-quality trial data.
But "narrow" doesn't mean "trivial." Hypoglycemia hits roughly 20% of basal insulin users each year and is a frequent driver of hospitalizations among older adults. Knowing which side effects actually warrant your attention, and which ones you can largely stop worrying about, changes how you approach insulin therapy day to day.
MedicationsMay 17, 2026
Fluoxetine, sold as Prozac, is one of the most widely prescribed antidepressants on the planet, and one of the most common fears people have about starting it is gaining weight. But when you look at the actual human trial data, the picture flips. Meta-analyses of randomized trials in overweight and obese adults show fluoxetine produces modest weight loss of roughly 1 to 3 kg compared to placebo, particularly at doses of 60 mg/day or higher over 12 weeks or less. A large systematic review of psychotropic medications found fluoxetine associated with an average 1.3 kg loss.
That's not a typo. The drug most people worry will make them heavier is, if anything, slightly more likely to make them lighter.
GLP-1May 17, 2026
In a trial of 27,564 patients followed for over two years, evolocumab (Repatha) cut LDL cholesterol by 59% and lowered major cardiovascular events by 15%, with no meaningful difference in adverse events versus placebo aside from a small uptick in injection-site reactions. Weight loss was not on the list of effects, then or in any subsequent analysis.
If you have heard that an injectable drug helps with weight, you are probably thinking of a different class. Wegovy, Zepbound, Ozempic, and Mounjaro are GLP-1 receptor agonists, designed specifically to drive weight loss. Repatha was designed for cholesterol.
They are all injections, administered weekly or monthly, and all expensive. They do not do the same thing.
GLP-1May 17, 2026
In a head-to-head trial of 338 adults with obesity, weekly semaglutide reduced body weight by about 16% while daily liraglutide reached just 6% over the same 68 weeks. That gap matters. The choice of GLP-1 drug, the dose, and how long you stay on it collectively determine whether you lose a modest amount of weight or a quarter of your starting body mass.
GLP-1 receptor agonists have become the most effective non-surgical weight loss treatments ever tested in large trials. But the category includes several different drugs with meaningfully different results, and the details determine what you can realistically expect.
